Therapeutic efficacy and safety of Xuebijing in traumatic brain injury: systematic review and meta-analysis
XBJ appears to be an effective and safe adjunctive therapy for TBI, improving neurological outcomes and reducing inflammatory responses. Dose-dependent effects support the optimization of treatment protocols.
Authors
- Junyuan Lv
- Hao Wen (ORCID: https://orcid.org/0000-0001-6987-0459)
- Boying Xiao (ORCID: https://orcid.org/0000-0002-7969-0504)
- Yihan Sun (ORCID: https://orcid.org/0000-0002-8944-3945)
- Jiaqi Li (ORCID: https://orcid.org/0000-0002-5210-3226)
- Ziqi Li (ORCID: https://orcid.org/0000-0002-2829-3146)
- Zhuoyu Li (ORCID: https://orcid.org/0009-0006-9858-6733)
- Ning He (ORCID: https://orcid.org/0000-0002-2371-4917)
- Miao Yu (ORCID: https://orcid.org/0000-0002-8298-1679)
- Xinyue Cui (ORCID: https://orcid.org/0000-0003-1349-433X)
- Zhijing Wei
Institutions
- Zunyi Medical University (CN)
- First Hospital of China Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.3389/fphar.2025.1669352
- Primary Topic
- Traumatic Brain Injury and Neurovascular Disturbances
- Type
- article
- Field-Weighted Citation Impact
- 0.00